Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneus Ltd. ( (AU:CMB) ) just unveiled an update.
Cambium Bio Limited has announced a change in its registered office and principal place of business to a new location in Bella Vista, NSW. This move is part of the company’s ongoing efforts to advance its pipeline of regenerative medicine products, focusing on ophthalmology and tissue repair, and reflects its commitment to improving patient outcomes through innovative biologics.
More about Regeneus Ltd.
Cambium Bio Limited is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The company’s proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio’s lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Additionally, the company’s stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 19,808
Technical Sentiment Signal: Sell
Current Market Cap: A$3.47M
For an in-depth examination of CMB stock, go to TipRanks’ Stock Analysis page.